Dual Targeting of the Androgen Receptor for Effective and Durable Control of Lethal Prostate Cancer [ 2017 - 2020 ]

Research Grant

[Cite as]

Researchers: Prof Wayne Tilley (Principal investigator) ,  Prof Gail Risbridger Dr Luke Selth Dr Renea Taylor

Brief description Preventing binding of androgens to the androgen receptor is the mainstay treatment for advanced prostate cancer, but resistance inevitably develops and the disease becomes lethal. We will develop a new drug that targets a part of the androgen receptor unrelated to its androgen binding function to overcome resistance to current therapy. As this drug will be effective in all stages of prostate cancer, it has high potential to improve survival outcomes for men with prostate cancer.

Funding Amount $AUD 969,621.45

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]